Medicine and Dentistry
Patient
100%
Rapamycin
33%
Stent
33%
Primary Percutaneous Coronary Intervention
29%
Polymer
27%
Inpatient
26%
ST Segment Elevation Myocardial Infarction
23%
Zotarolimus
23%
Follow up
22%
Umirolimus
21%
Target Lesion
21%
Lesion
19%
Diabetes Mellitus
16%
Noninferiority Trial
15%
Therapeutic Procedure
15%
Myocardial Infarction
14%
Heart Death
14%
Revascularization
13%
Heart Failure
11%
Infarction
11%
Intention-to-Treat Analysis
11%
Target Lesion Revascularization
10%
Artery
10%
Conditioning
9%
Fibrinolysis
9%
Mortality
9%
Everolimus
8%
Percutaneous Coronary Intervention
7%
Drug-Eluting Stent
7%
Cardiovascular System
7%
Hazard Ratio
7%
Stent Thrombosis
7%
Randomized Controlled Trial
6%
Patient with Diabetes
6%
Acute Heart Infarction
5%
Intravascular Ultrasound
5%
Artery Intima Proliferation
5%
Analysis
5%
Nursing and Health Professions
Stent
76%
Patient
48%
Inpatient
29%
Polymer
28%
Rapamycin
27%
Diabetes Mellitus
19%
ST Segment Elevation Myocardial Infarction
18%
Follow up
17%
Implantation
17%
Zotarolimus
16%
Procedures
14%
Percutaneous Coronary Intervention
11%
Drug Eluting Coronary Stent
11%
Heart Failure
11%
Clinical Outcome
10%
Drug Eluting Stent
10%
Mortality
9%
Heart Infarction
9%
Heart Death
9%
Intention to Treat Analysis
8%
Hospitalization
8%
Stent Thrombosis
7%
Confidence Interval
7%
Chronic Total Occlusion
6%
Acute Heart Infarction
5%
Umirolimus
5%
Target Lesion Revascularization
5%
Patient with Diabetes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Polymer
39%
Rapamycin
37%
Diabetes Mellitus
28%
Umirolimus
25%
Zotarolimus
23%
ST Segment Elevation Myocardial Infarction
20%
Heart Infarction
13%
Infarction
11%
Stent
11%
Heart Death
9%
Mortality
9%
Stent Thrombosis
8%
Heart Failure
5%
Noninferiority Trial
5%
